IRLAB's pipeline has been generated by the company's proprietary systems biology-based research platform Integrative Screening Process (ISP). Headquartered in Sweden, IRLAB is listed on Nasdaq ...

IRLAB held a capital markets day on October 17 where investors, analysts and financial media were updated on the company's drug development portfolio and growth strategy. Presentations were held by ...

GOTHENBURG, SE / ACCESS Newswire / August 11, 2025 / IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announces ...

IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announces that the nomination committee ahead of the annual general ...

The latest announcement is out from IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ). IRLAB Therapeutics AB announced that the European Patent Office intends to grant ...

GOTHENBURG, SWEDEN / ACCESS Newswire / April 25, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - Gothenburg, Sweden, April 25, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company ...

STOCKHOLM, Nov. 6, 2019 /PRNewswire/ -- IRLAB announced today that drug candidates IRL942 and IRL1009 have been granted composition of matter patents in the US and Europe from respective authorities.

Ipsen obtains the exclusive worldwide rights to develop and commercialize the investigational treatment mesdopetam which is based on a novel mechanism of action Mesdopetam, an oral dopamine ...

GOTHENBURG, SWEDEN / ACCESSWIRE / December 27, 2023 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA) Gothenburg, Sweden, December 27, 2023 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company ...